Mithramycin is a gene-selective sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration.
Journal of Neuroscience.
Times cited: 63
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington's disease.
EMBO Molecular Medicine.
Times cited: 76